
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Denver - Two bills introduced in Colorado's State Legislatureare the latest entries in a nationwide effort to rein in drug costs withrestricted formularies.